大肠杆菌耐热肠毒素基因多拷贝串联表达及其单克隆抗体的制备

为制备具有免疫原性的重组大肠杆菌耐热肠毒素蛋白(STp)及抗STp特异性单克隆抗体(MAb),本研究将5拷贝estp串联,克隆于p GEX-6p-1中,构建重组表达质粒p GEX-estp5-his,并转化于大肠杆菌中进行重组蛋白STp5-His(r STp5-His)的表达。以r STp5-His为免疫原,重组蛋白MBP-5STp为检测抗原,制备和筛选阳性杂交瘤细胞株,并采用western blot、阻断ELISA方法对MAb进行鉴定。结果显示,r STp5-His主要以包涵体形式表达,大小约为38 ku,具有良好的免疫原性,以其作为免疫原制备了4株能够识别天然STp的MAb,特异性良好。研究表明,多拷贝基因串联表达可以制备具有免疫原性的重组STp蛋白,所制备的MAb为天然STp和重组STp蛋白检测方法的建立奠定了基础。     

猪肺炎支原体P52蛋白的原核表达及抗血清制备

为表达猪肺炎支原体(Mhp)P52蛋白及制备其血清,本实验利用PCR从Mhp J株扩增P52基因,克隆到表达载体pET-30a中,获得重组质粒pET-P52,经IPTG诱导,通过SDS-PAGE和western blot检测重组蛋白表达及其免疫学活性.以该重组蛋白为抗原免疫兔制备抗血清,采用间接ELISA检测抗血清效价,并利用抗血清通过间接免疫荧光检测P52基因在AD-293细胞中的表达情况.结果表明,PCR扩增目的基因为1 202 bp,SDS-PAGE检测重组蛋白大小约52 ku,其表达量占菌体总蛋白的28%.Western blot检测表明,目的蛋白能与Mhp阳性血清发生特异性反应,具有良好的免疫活性.间接免疫荧光检测到P52基因在AD-293细胞中表达.本研究为构建P52蛋白腺病毒载体疫苗奠定了基础.     

猪肺炎支原体168弱毒株P65基因的原核表达及鉴定

研究猪肺炎支原体168(Mycoplasma hyopneumoniae 168,Mhp168)弱毒株重组蛋白p65的免疫原性。根据GenBank中Mhp168弱毒株P65基因的开放阅读框设计特异性引物,进行PCR扩增,构建原核表达载体pET-28a-P65,经原核表达并纯化获得的重组蛋白与佐剂以体积比1∶1乳化后免疫注射小鼠,通过酶联免疫吸附试验(ELISA)测定小鼠血清的抗体效价;选取抗体效价较高的小鼠进行攻毒试验。经间接ELISA证明,重组蛋白p65具有良好的免疫原性,血清效价为1∶12 800。攻毒试验证明,p65重组蛋白疫苗的保护率可达80%,证明重组蛋白p65具有良好的免疫原性。     

非洲猪瘟病毒B438L蛋白的原核表达及其多克隆抗体的制备与鉴定

本研究旨在通过构建非洲猪瘟病毒（ASFV）B438L基因原核表达系统表达p49重组蛋白,并制备抗p49蛋白的多克隆抗体。根据ASFV Georgia 2007/1（GenBank登录号：FR682468.1）公布的基因序列合成B438L基因,并将其插入pET-28a （+）载体,构建pET-28a-B438L重组质粒,转化大肠杆菌BL21（DE3）感受态细胞,在16 ℃经1 mmol/L IPTG诱导12 h,通过SDS-PAGE对重组蛋白表达形式进行分析;利用串联质谱技术鉴定重组蛋白是否正确表达;将纯化的p49重组蛋白免疫小鼠制备鼠源抗p49多克隆抗体,利用间接ELISA方法测定该多克隆抗体的效价,并以间接免疫荧光试验及Western blotting检测该多克隆抗体的特异性。结果显示,试验成功构建了pET-28a-B438L重组质粒,转化大肠杆菌BL21（DE3）感受态细胞后经诱导表达获得了p49重组蛋白,重组蛋白主要以包涵体形式表达,大小约为60 ku;串联质谱技术进一步证实该蛋白为p49。间接ELISA检测制备的鼠源抗p49多克隆抗体效价达1：64 000,间接免疫荧光试验及Western blotting结果表明制备的鼠源抗p49多克隆抗体能特异性识别p49蛋白。以上结果表明,该原核表达的ASFV p49重组蛋白具有良好的免疫原性,利用表达的p49重组蛋白制备的多克隆抗体具有较高的抗体效价和特异性,为进一步研究ASFV p49蛋白的结构与功能、研制相关的ASFV诊断试剂及疫苗提供了生物材料。     

绵羊肺炎支原体P109'蛋白的分子特征及抗原性分析

为了研究绵羊肺炎支原体P109'蛋白分子结构特征与抗原性,本研究对p109'基因经生物信息学分析,通过PCR对其部分基因片段进行扩增,将其克隆至p ET-32a(+)以构建原核表达载体,诱导后经大肠杆菌表达体系进行原核表达,并通过Western-blot分析该蛋白的反应原性。结果表明p109'基因与殊异支原体编码假定蛋白基因MDIS-01350、猪肺炎支原体黏附相关基因p102及编码P102样蛋白基因mhp217之间具有较高的同源性。重组P109'蛋白以包涵体形式在大肠杆菌BL21(DE3)中成功得到表达;经纯化后的重组蛋白与山羊抗绵羊肺炎支原体全菌血清发生结合反应,表明P109'蛋白具有良好的反应原性,为后期建立绵羊肺炎支原体特异快速诊断技术奠定基础。     

猪磷酸酪氨酸互作结构域1基因的融合表达及其多克隆抗体的制备和鉴定

本文旨在通过原核表达获得猪磷酸酪氨酸互作结构域1(p PID1)重组蛋白,并制备p PID1多克隆抗体。将p PID1基因插入p ET28a(+),构建重组p ET28a(+)-p PID1大肠杆菌表达质粒,然后将重组质粒p ET28a(+)-p PID1转化到大肠杆菌BL21感受态细胞中,获得的重组子以不同异丙基硫代-β-D-半乳糖苷(IPTG)浓度、温度和时间诱导,确定p PID1融合蛋白表达的最适条件。将表达产物经镍离子-亚氨基二乙酸(Ni2+-IDA)亲和层析纯化后进行基质辅助激光解析电离飞行时间质谱(MALDI-TOF-MSMS)鉴定。同时,将纯化获得的p PID1融合蛋白免疫SD大鼠,制备p PID1多克隆抗体,并检测抗体效价。结果表明:p PID1融合蛋白表达的最佳条件为30℃以0.1 mmol/L IPTG诱导4 h;纯化的融合蛋白经MALDI-TOF-MSMS鉴定为p PID1;特异性的p PID1多克隆抗体成功制备,抗体效价为1∶20 480。本试验成功制备了高纯度的重组p PID1及其多克隆抗体。     

非洲猪瘟病毒P30蛋白在昆虫细胞中的表达

为表达非洲猪瘟病毒(ASFV)P30蛋白,本研究采用PCR方法扩增ASFV p30基因,并克隆至p OET-1载体中构建重组质粒p OET-P30,将其与flash BAC DNA共转染Sf9昆虫细胞,制备了表达P30蛋白的重组杆状病毒,并通过SDS-PAGE和western blot对重组杆状病毒进行鉴定。结果显示,表达的重组蛋白约为30 ku,能够与His标签单克隆抗体和ASF阳性血清发生特异性反应。以纯化的重组P30蛋白包被ELISA板对相关抗体进行检测,结果显示该重组蛋白仅与ASFV阳性血清发生反应,而与其他疫病阳性血清均无交叉反应,该抗原具有良好的反应原性。该蛋白的表达为ASF血清学检测方法的建立奠定了基础。     

传染性法氏囊病超强病毒株VP2基因原核表达及其免疫原性检测

为检测传染性法氏囊病超强毒株(vvIBDV)重组VP2蛋白的免疫原性,本研究利用RT-PCR方法扩增vvIBDV的结构蛋白VP2基因,并将其克隆到表达载体pGEX-4T-3中,构建重组表达质粒pGEX-VP2。将其转化受体菌E.coli BL21(DE3)plysS,经IPTG诱导后,SDS-PAGE电泳和western blot分析表明,表达的重组蛋白约69 ku,并以包涵体形式存在。表达的重组蛋白经纯化后,免疫6周龄BALB/c小鼠制备免疫血清,ELISA分析表明制备的血清效价在1∶5 120以上,表明vvIBDV VP2具有良好的免疫原性,为建立vvIBDV的ELISA检测方法提供了试验依据。     

非洲猪瘟病毒p11.5蛋白的表达及其单克隆抗体的制备

为了制备非洲猪瘟病毒(African swine fever virus, ASFV)p11.5蛋白的特异性单克隆抗体,利用大肠杆菌表达系统,将密码子优化后的ASFV p11.5基因序列连接表达载体pET28a-SUMO,构建pET28a-SUMO-p11.5原核表达质粒,获得了可溶性的ASFV p11.5蛋白。经Western blot鉴定,重组ASFV p11.5蛋白可被ASFV标准阳性血清特异性识别,表明其具有良好的反应原性。将纯化后的p11.5蛋白免疫BALB/c小鼠,通过杂交瘤细胞法,制备了4株可稳定分泌抗ASFV p11.5蛋白单克隆抗体的杂交瘤细胞株。3株单克隆抗体重链亚类为IgG1,1株重链亚类为IgG2a,轻链亚类均为κ。采用p11.5蛋白为包被抗原的间接ELISA方法检测单克隆抗体的效价均不低于1∶102.4×10~4。经间接免疫荧光试验(IFA)鉴定,4株单克隆抗体,均不与猪瘟病毒、猪繁殖与呼吸综合征病毒、猪伪狂犬病病毒、猪圆环病毒2型、猪流行性腹泻病毒发生交叉反应,但均能与ASFV反应,表明单克隆抗体具有良好的特异性和反应性。本试验为p11.5蛋白结构功能、免疫学特性及ASFV诊断试剂产品的研究提供了重要的生物材料。     

金黄色葡萄球菌新型肠毒素Ⅰ型蛋白的表达研究

为了研究金黄色葡萄球菌新型肠毒素Ⅰ型的检测方法,诱导融合表达并纯化金黄色葡萄球菌肠毒素Ⅰ型蛋白,试验根据Gen Bank中SEⅠ的序列设计一对特异性引物,采用PCR技术从金黄色葡萄球菌中扩增出新型肠毒素Ⅰ型基因,亚克隆入p EASY-E1载体中,构建重组质粒p EASY-E1-SEⅠ,以IPTG诱导表达,镍柱纯化表达蛋白,用His标签单克隆抗体进行免疫印迹分析验证融合蛋白的表达。结果表明:成功扩增出SEⅠ基因,片段大小为507 bp,重组质粒高效表达SEⅠ融合蛋白,经SDS-PAGE鉴定成功表达了分子质量约为26 ku的重组蛋白,Western-blot检测表明目的蛋白具有良好的免疫原性。说明表达系统p EASY-E1/BL21能高效表达金黄色葡萄球菌新型肠毒素Ⅰ蛋白。     

副猪嗜血杆菌rfaD基因的克隆及原核表达

rfaD基因编码ADP-L-甘油-D-甘露庚糖-6-异构体酶,缺失该基因会导致LOS糖链缩短和疏水性增强,从而影响细菌的致病性。为进一步探索副猪嗜血杆菌(Haemophilus parasuis,Hps)ADP-L-甘油-D-甘露庚糖-6-异构体酶的功能,本研究对Hps SC096 株rfaD基因进行克隆及原核表达。根据GenBank上登录的NC_011852序列,设计引物扩增rfaD基因,获得927 bp目的片段,将其克隆至pMD19-T载体。经送样测序鉴定正确后,连接到pET-32a(+)上进行原核表达,并用IPTG诱导,将诱导产物进行SDS-PAGE和Western blotting分析。SDS-PAGE结果显示,H.parasuis rfaD基因能在E.coli BL21(DE3)中表达,重组蛋白分子质量约为50 ku,与预期分子质量大小一致。Western blotting分析结果表明,该蛋白质能与H.parasuis血清4型阳性高免血清产生特异性结合反应,具较好的反应原性。     

副猪嗜血杆菌OMP5的克隆表达及其对豚鼠免疫保护作用

根据GenBank中登录的副猪嗜血杆菌外膜蛋白P5(outer membrane protein P5,OMP5)基因序列设计1对特异性引物,以江西分离株NC0807基因组DNA为模板,扩增出OMP5基因。将其克隆到pET-28a(+)中,构建重组表达质粒pET-28a-OMP5,质粒转化大肠杆菌BL21(DE3),通过SDS-PAGE和Western blotting分析重组蛋白的表达情况和反应原性。重组蛋白经镍柱亲和层析纯化后免疫豚鼠,测定其免疫原性和保护效率。结果表明,重组蛋白在大肠杆菌中获得了高效表达。表达的蛋白分子质量约为43 ku,能被副猪嗜血杆菌阳性血清识别。动物试验结果表明,重组蛋白免疫后能诱导产生高水平的OMP5特异性抗体,并可显著保护豚鼠抵抗副猪嗜血杆菌强毒菌株的攻击,提示OMP5是副猪嗜血杆菌的保护性抗原。     

Immunological Identification and Characterization of Extracellular Serine Protease-Like Protein Encoded in a Putative espP2 Gene of Haemophilus parasuis

Haemophilus parasuis is known to produce a group of virulence-associated autotransporter (AT) proteins, VtaAs; however, no other ATs have been characterized yet. On the basis of the reported sequence of a putative espP2 gene for extracellular serine protease (ESP)-like protein of H. parasuis, this putative AT gene was successfully amplified from H. parasuis serotype 5 field strain HPS0819, cloned and sequenced. The confirmed ORF sequence showed 100% identity with the reported putative espP2 gene. The recombinant ESP-like protein purified from Escherichia coli with a pET expression system was used for immunological characterization. An approximately 85 kDa antigen was detected in cultured H. parasuis by using antiserum to the purified ESP-like protein, and antibodies against the recombinant ESP-like protein were detected in a selected serum from pigs with experimental H. parasuis infection. The results indicated that H. parasuis could produce ESP-like protein in vitro and in vivo. In an immune protection study using guinea pigs, 6 out of 10 animals immunized with the recombinant ESP-like protein survived after challenge with 5 × 10(9) bacteria of strain HPS0819, whereas 7 out of 10 animals immunized with formalin-inactivated H0819 bacterin survived after challenge. The results suggest that ESP-like protein could be one of the vaccine antigen candidates for H. parasuis infection.     

副猪嗜血杆菌血清5型TbpA蛋白的表达及其免疫原性分析

为原核表达副猪嗜血杆菌血清5型TbpA蛋白,本研究利用特异性引物扩增tbpA基因,并将其克隆到pMD 18-T载体中进行序列测定.再将其亚克隆于pET-28a中构建重组表达质粒pET-tbpA.将其转化受体菌E.coli BL21 (DE3),经IPTG诱导后,SDS-PAGE电泳和western blot分析表明,表达的重组蛋白约106 ku,并以包涵体形式存在.表达的重组蛋白经纯化后,免疫6周龄昆明小鼠制备免疫血清,ELISA分析表明制备的血清抗体效价在1∶3 200以上,表明TbpA具有良好的免疫原性.     

Evaluation of recombinant proteins of Haemophilus parasuis strain SH0165 as vaccine candidates in a mouse model

The recently completed genome sequence of Haemophilus parasuis strain SH0165 allowed us to screen putative OMPs for the development of recombinant vaccines. The objective of this study was to evaluate the immunogenicity and protective efficacy of three OMPs of H. parasuis. Three putative OMPs (SmpA, YgiW and FOG) were cloned, expressed and purified by Ni affinity chromatography using nitriloacetic acid resin. Mice were immunized either individually (individual protein, IP) or synergistically (synergistic protein, SP) with the recombinant proteins. A significant increase in IgG titer was detected in all protein-immunized mice. Isotyping studies revealed that the antibodies produced were predominantly IgG2a-type, indicating a predominant Th1 response. A significant increase was observed in IL-2, IL-4 and IFN-γ levels in the culture supernatants of splenocytes isolated from immunized mice. Furthermore, mice were challenged intraperitoneally with 6×10(9)CFU (5×LD(50)) of highly virulent homologous serovar 5 strain (SH0165) or 7.0×10(9) CFU (5×LD(50)) of the heterologous serovar 4 strain (MD0322) at fourteen days after the last immunization. All of the recombinant proteins enhanced survival and reduced histopathological lesions. Our results indicated that the three OMPs showed protection both individually and synergistically against infection with the highly virulent H. parasuis in mice.     

副猪嗜血杆菌CDT亚基原核表达及其抗原性鉴定

为原核表达副猪嗜血杆菌(H.parasuis)CDT毒素并检测其在体外培养时的分泌表达情况,本实验将切除信号肽的CDT毒素的3个亚基基因分别克隆于pET-28a载体中在大肠杆菌进行表达,并将重组蛋白经亲和层析纯化后,免疫兔制备抗血清,用于鉴定H.parasuis体外培养时CDT分泌表达情况。结果表明CDT毒素3个亚基均在Rosetta菌株中得到表达,其中cdtB约为28.2 ku,符合预期大小,而cdtA和cdtC亚基比预期的23.5 ku和17.4 ku略大。表达的3个重组蛋白可以被自然感染猪血清识别,表明其具有良好的反应原性,同时也表明H.parasuis在猪体内定殖或感染过程中分泌CDT。制备的抗血清可以与体外培养H.parasuis的分泌蛋白中的CDT亚基反应,表明重组蛋白具有良好的免疫原性,同时也表明H.parasuis体外培养时也分泌CDT。     

Evaluation of survival of Actinobacillus pleuropneumoniae and Haemophilus parasuis in four liquid media and two swab specimen transport systems

OBJECTIVE: To determine duration and rates of recovery of Actinobacillus pleuropneumoniae and Haemophilus parasuis from 4 liquid media and 2 swab specimen transport systems and compare findings with those of Escherichia coli. SAMPLE POPULATION: One strain each of A pleuropneumoniae (biovar 1, serotype 1), H parasuis (serovar 5), and E coli (serotype O149:K91:H19). PROCEDURE: Strains were incubated in brain heart infusion broth supplemented with horse serum and other nutrients or in horse serum alone, with and without nicotinamide-adenine dinucleotide in both instances, for 150 days at 4 degrees C or room temperature (21 degrees C). Similarly, strains were tested in Stuart and Amies transport systems after storage at room temperature for 8 days. RESULTS: Colony counts greater than those of the initial inoculum were observed after incubation in horse serum for A pleuropneumoniae but not for H parasuis. Overall, incubation at 4 degrees C in the 4 liquid media resulted in longer recovery duration and higher rates than at room temperature. Culture of H parasuis resulted in lower recovery rates and shorter durations of recovery than culture of A pleuropneumoniae, except for culture in horse serum. Haemophilus parasuis survived longer than A pleuropneumoniae in the transport systems, and all organisms survived longer in the Amies system. CONCLUSIONS AND CLINICAL RELEVANCE: Survival of A pleuropneumoniae and H parasuis indicated that horse serum prolongs survivability, which may result in exposure of more animals during a prolonged period. The Amies system might be a good choice for collection of clinical samples from animals, especially for recovery of H parasuis.     

副猪嗜血杆菌间接ELISA抗体检测方法的建立

采用福尔马林灭活的副猪嗜血杆菌全菌体作为包被抗原,建立了检测副猪嗜血杆菌抗体的间接ELISA方法。经试验确定副猪嗜血杆菌全菌体的包被浓度为2·24×107CFU/孔、检测血清为1∶200稀释,同时确立了间接ELISA的最佳反应条件。该方法有很高的特异性和重复性,14个发病猪场100份血清检测结果Hps抗体阳性检出率为94%,明显高于细菌分离鉴定检测结果。     

Purification and renaturation of membrane neuraminidase from Haemophilus parasuis

Haemophilus parasuis, which causes polyserositis, polysynovitis, meningitis, septicemia, and pneumonia in pigs, has emerged as an increasing problem in modern swine production systems. Co-factors for and the pathogenesis of H. parasuis disease are not defined. One of the potential virulence factors of H. parasuis is its neuraminidase (sialidase). While purifying the H. parasuis neuraminidase from the membrane fraction, we developed a protocol to renature enzymatic activity after enzyme preparations were resolved electrophorectically in denaturing polyacrylamide gels. The H. parasuis neuraminidase co-resolved with recombinant neuraminidase of Vibrio cholera; thus its apparent molecular mass is 82 kilodalton (kDa). The H. parasuis neuraminidase was associated with the membrane fraction and the purification protocol removed over 99% of the H. parasuis cell protein while retaining over 90% of the neuraminidase activity. Purified protein will provide another avenue to clone the neuraminidase gene that has been refractory to cloning and the protocol will be a means to purify recombinant protein.     

副猪嗜血杆菌高密度发酵工艺研究

旨在建立副猪嗜血杆菌高密度发酵工艺。通过对TSB、BH1、LB培养基进行比较，选择TSB培养基进行优化，利用优化后的培养基对副猪嗜血杆菌在10L发酵罐中进行高密度发酵培养。结果表明，血清4型JS株的活菌数达到2．5×10^10CFU／mL，血清5型ZJ株的活菌数达到2．5×10^10CFU／mL，且通过批次补料与流加相结合的工艺使关键成本血清的使用量降低了1／2。在1000L发酵规模上进行连续3批的发酵试验．经验证该工艺可用于副猪嗜血杆菌灭活疫苗抗原的规模化生产。对3批发酵抗原利用替代动物豚鼠进行动物实验，结果显示抗原均合格。研究结果为国内副猪嗜血杆菌流行菌株血清4型和5型二价灭活疫苗的规模化生产提供了理论依据。